S R Granter

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma
    S R Granter
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Am J Dermatopathol 23:185-9. 2001
  2. ncbi Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: a clinicopathologic study of 10 cases on the spectrum of so-called 'malignant blue nevus'
    S R Granter
    Department of Pathology and the Division of Dermatopathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Surg Pathol 25:316-23. 2001
  3. ncbi Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma
    Scott R Granter
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Appl Immunohistochem Mol Morphol 10:47-51. 2002
  4. ncbi Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation
    S R Granter
    Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mod Pathol 14:6-9. 2001
  5. ncbi Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature
    A Zembowicz
    Division of Dermatopathology, Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Dermatopathol 23:167-75. 2001
  6. ncbi Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation
    Bin Zheng
    Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Mol Cell 33:237-47. 2009
  7. ncbi Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers
    Ian J Davis
    Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:473-84. 2006
  8. ncbi Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    Levi A Garraway
    Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 436:117-22. 2005
  9. ncbi Cytologic findings in granular cell tumors, with emphasis on the diagnosis of malignant granular cell tumor by fine-needle aspiration biopsy
    T J Wieczorek
    Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Cancer 93:398-408. 2001
  10. ncbi My approach to atypical melanocytic lesions
    K S Culpepper
    Division of Dermatopathology, Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 05464, USA
    J Clin Pathol 57:1121-31. 2004

Collaborators

Detail Information

Publications19

  1. ncbi Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma
    S R Granter
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Am J Dermatopathol 23:185-9. 2001
    ..Nevertheless, we believe that diffuse positive staining for D5 when taken in clinical, histologic and immunohistochemical context may be diagnostically useful in selected cases of melanoma...
  2. ncbi Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: a clinicopathologic study of 10 cases on the spectrum of so-called 'malignant blue nevus'
    S R Granter
    Department of Pathology and the Division of Dermatopathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Surg Pathol 25:316-23. 2001
    ..Three patients died of disease. Malignant blue nevus is a heterogeneous group of melanomas that are highly aggressive and often lethal, with a propensity for metastasis to the lymph nodes and lungs...
  3. ncbi Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma
    Scott R Granter
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Appl Immunohistochem Mol Morphol 10:47-51. 2002
    ..In particular, D5 is helpful in the evaluation of epithelioid neoplasms, but not spindle-cell tumors...
  4. ncbi Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation
    S R Granter
    Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mod Pathol 14:6-9. 2001
    ..D5 immunoreactivity in clear cell sarcoma provides further evidence for melanocytic differentiation in this unusual tumor...
  5. ncbi Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature
    A Zembowicz
    Division of Dermatopathology, Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Dermatopathol 23:167-75. 2001
    ..Our data and a review of the literature do not support the notion that nevoid melanoma has a better prognosis than ordinary melanoma...
  6. ncbi Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation
    Bin Zheng
    Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Mol Cell 33:237-47. 2009
    ..Our findings provide a molecular linkage between the LKB1-AMPK and the RAF-MEK-ERK pathways and suggest that suppression of LKB1 function by B-RAF V600E plays an important role in B-RAF V600E-driven tumorigenesis...
  7. ncbi Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers
    Ian J Davis
    Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:473-84. 2006
    ..Seemingly unrelated tumors thus employ distinct strategies to oncogenically dysregulate the MiT family, collectively broadening the definition of MiT-associated human cancers...
  8. ncbi Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    Levi A Garraway
    Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 436:117-22. 2005
    ..Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression...
  9. ncbi Cytologic findings in granular cell tumors, with emphasis on the diagnosis of malignant granular cell tumor by fine-needle aspiration biopsy
    T J Wieczorek
    Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Cancer 93:398-408. 2001
    ..CONCLUSIONS: Malignant GCTs have characteristic cytologic features that differ from those of benign GCTs. However, morphologic heterogeneity precludes definitive classification of some tumors by cytologic features alone...
  10. ncbi My approach to atypical melanocytic lesions
    K S Culpepper
    Division of Dermatopathology, Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 05464, USA
    J Clin Pathol 57:1121-31. 2004
    ..Complete or large excision of all clinically atypical naevi permits histological assessment of the entire lesion, and in most cases spares the patient the need for further surgical intervention...
  11. ncbi Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 12:786-93. 1999
    ..001). The frequencies of expression of ER and PR in SGCs and BCs metastatic to skin were not significantly different...
  12. ncbi Integrative genome comparison of primary and metastatic melanomas
    Omar Kabbarah
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 5:e10770. 2010
    ....
  13. ncbi Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases
    J F Krane
    Division of Cytology, Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 93:8-15. 2001
    ..Papanicolaou smear sensitivity for cervical adenocarcinoma (CVCA) is not well established. Also uncertain are the relative contributions to falsely negative diagnoses of sampling, screening, and interpretive errors...
  14. ncbi BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma
    E Elizabeth Patton
    Howard Hughes Medical Institute, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
    Curr Biol 15:249-54. 2005
    ....
  15. ncbi Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche
    Emi K Nishimura
    Department of Pediatric Hematology Oncology, Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, Boston Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 307:720-4. 2005
    ..Furthermore, physiologic aging of melanocyte stem cells was associated with ectopic pigmentation or differentiation within the niche, a process accelerated by mutation of the melanocyte master transcriptional regulator Mitf...
  16. ncbi Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene
    Minjung Kim
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Cell 125:1269-81. 2006
    ..Thus, comparative oncogenomics has enabled the identification and facilitated the validation of a highly relevant cancer gene governing metastatic potential in human melanoma...
  17. ncbi Merkel cell carcinoma: lack of KIT positivity and implications for the use of imatinib mesylate
    Qinghong Yang
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Appl Immunohistochem Mol Morphol 17:276-81. 2009
    ..Indeed, our review of the literature and the apparent lack of efficacy of imatinib mesylate for MCC in a recent phase 2 trial suggest a minor role for KIT signaling in MCC tumorigenesis...
  18. ncbi Desmoplastic/spindle cell squamous cell carcinoma of the skin. A diagnostically challenging tumor mimicking a scar: clinicopathologic and immunohistochemical study of 6 cases
    Elsa F Velazquez
    Departments of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am J Dermatopathol 32:333-9. 2010
    ..Careful search for atypical features and squamous differentiation, immunohistochemical studies, and, in some cases, deeper sections are required to establish the diagnosis...
  19. ncbi Pagetoid lesions of the vulva: a collision between malignant melanoma and extramammary Paget disease
    Sarah J Hill
    Harvard MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, USA
    Int J Gynecol Pathol 27:292-6. 2008
    ..Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy...